https://www.pharmaradar360.com/article/british-sign-language-bsl-5-year-plan-department-of-health-and-social-care-30cc27cd2ce930d6Pharma Surgeen2026-07-15T11:13:31.000ZBritish Sign Language (BSL) 5-year plan: Department of Health and Social Carehttps://www.pharmaradar360.com/article/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-bd4ef0e000a66049Pharma Surgeen2026-07-15T11:00:00.000ZMerck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026https://www.pharmaradar360.com/article/johnson-johnson-shares-fall-despite-better-than-expected-results-724a90bfb470a21ePharma Surgeen2026-07-15T10:56:30.000ZJohnson & Johnson shares fall despite better-than-expected resultshttps://www.pharmaradar360.com/article/sichuan-kelun-biotech-biopharmaceutical-and-harbour-biomed-receive-nmpa-approval-9c99f222ca05821aPharma Surgeen2026-07-15T10:50:48.000ZSichuan Kelun-Biotech Biopharmaceutical and Harbour Biomed Receive Nmpa Approval of Ind Application for Skb575/Hbm7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-50a0267f52b4a72cPharma Surgeen2026-07-15T10:45:00.000ZKEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapyhttps://www.pharmaradar360.com/article/biogen-shares-slide-as-diranersen-data-raise-dosing-question-00a9d85654d2a198Pharma Surgeen2026-07-15T10:42:57.000ZBiogen shares slide as diranersen data raise dosing questionhttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-collection-verification-and-reporting-of-safety-ev-f9fb7893827ee468Pharma Surgeen2026-07-15T10:36:39.000ZClinical trials for medicines: collection, verification and reporting of safety eventshttps://www.pharmaradar360.com/article/prac-6-9-2026-b775a7fed8b8bd76Pharma Surgeen2026-07-15T10:31:50.000ZΚύρια σημεία συνεδρίασης της Επιτροπής Αξιολόγησης Κινδύνου Φαρμακοεπαγρύπνησης (PRAC), 6 – 9 Ιουλίου 2026https://www.pharmaradar360.com/article/government-and-joe-wicks-support-families-to-stay-active-514c95d4f74fc5d4Pharma Surgeen2026-07-15T10:29:24.000ZGovernment and Joe Wicks support families to stay activehttps://www.pharmaradar360.com/article/sinovac-biotech-nasdaq-sva-extends-55-per-share-dividend-deadline-7d3cd79fee7565aaPharma Surgeen2026-07-15T10:10:01.000ZSinovac Biotech (NASDAQ: SVA) extends $55 per share dividend deadlinehttps://www.pharmaradar360.com/article/corporate-report-medicines-and-healthcare-products-regulatory-agency-annual-repo-4738f50190473de0Pharma Surgeen2026-07-15T10:04:00.000ZCorporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2025 to 2026https://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-announce-nmpa-approval-of-ind-application-for-h-7c5e7d6e53eee0ccPharma Surgeen2026-07-15T10:01:00.000ZHarbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-s-eb7b12e2b66a8faePharma Surgeen2026-07-15T10:00:00.000ZKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-modifying-a-clinical-trial-approval-4b4a6047f9614fbaPharma Surgeen2026-07-15T09:58:11.000ZClinical trials for medicines: modifying a clinical trial approvalhttps://www.pharmaradar360.com/article/a-complete-guide-to-pharmaceutical-ingredients-serum-pharma-s-apis-plant-extract-1a8a933d216f179dPharma Surgeen2026-07-15T09:30:00.000ZA Complete Guide to Pharmaceutical Ingredients: Serum Pharma’s APIs, Plant Extracts & Nutraceutical Solutionshttps://www.pharmaradar360.com/article/pathogen-genomics-at-porton-down-a47255a8a5e18febPharma Surgeen2026-07-15T09:20:46.000ZPathogen genomics at Porton Downhttps://www.pharmaradar360.com/article/zydus-lifesciences-seals-150-million-sterling-biotech-deal-f7d126b357fa04a4Pharma Surgeen2026-07-15T09:12:13.000ZZydus Lifesciences seals $150 million Sterling Biotech dealhttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-15T09:00:05.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/framework-agreements-between-the-department-of-health-and-social-care-and-its-ar-10908850a6438af4Pharma Surgeen2026-07-15T09:00:03.000ZFramework agreements between the Department of Health and Social Care and its arm’s length bodieshttps://www.pharmaradar360.com/article/framework-agreement-between-dhsc-and-the-uk-health-security-agency-2026-to-2029-a07733552c8962cePharma Surgeen2026-07-15T09:00:00.000ZFramework agreement between DHSC and the UK Health Security Agency: 2026 to 2029https://www.pharmaradar360.com/article/hhs-and-fda-respond-to-dea-s-action-on-kratom-related-products-a2d58e5c5f700537Pharma Surgeen2026-07-15T09:00:00.000ZHHS and FDA Respond to DEA’s Action on Kratom-Related Productshttps://www.pharmaradar360.com/article/harel-insurance-investments-financial-services-ltd-increases-position-in-teva-ph-15ed565596b69f92Pharma Surgeen2026-07-15T08:38:52.000ZHarel Insurance Investments & Financial Services Ltd. Increases Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/a-new-biotech-startup-tries-to-tackle-obesity-but-not-in-the-way-you-might-expec-afdfee9cabfae5eaPharma Surgeen2026-07-15T08:34:41.000ZA new biotech startup tries to tackle obesity, but not in the way you might expecthttps://www.pharmaradar360.com/article/biotech-firm-that-went-viral-for-plans-to-create-nonsentient-humanoids-for-organ-3d03aa2c88a2b234Pharma Surgeen2026-07-15T08:34:00.000ZBiotech firm that went viral for plans to create 'nonsentient humanoids' for organ harvesting now says it was never truehttps://www.pharmaradar360.com/article/ukhsa-flusurvey-surveillance-system-9eb06a6a8ee4950aPharma Surgeen2026-07-15T08:30:13.000ZUKHSA FluSurvey surveillance systemhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-15T08:30:13.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-95d573354d6fb70dPharma Surgeen2026-07-15T08:30:13.000ZUK Clinical Research Delivery key performance indicatorshttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-4b8ae69acc200783Pharma Surgeen2026-07-15T08:30:11.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/it-looks-done-common-bbq-blunders-and-how-to-avoid-them-ac5818a1039bd58aPharma Surgeen2026-07-15T08:30:11.000Z'It looks done': Common BBQ blunders and how to avoid themhttps://www.pharmaradar360.com/article/bloodborne-virus-bbv-related-infection-control-breaches-management-toolkit-1288ed113665206cPharma Surgeen2026-07-15T08:30:10.000ZBloodborne virus (BBV) related infection control breaches: management toolkithttps://www.pharmaradar360.com/article/tuberculosis-in-england-2025-report-c1ff658160421e4bPharma Surgeen2026-07-15T08:21:59.000ZTuberculosis in England, 2025 reporthttps://www.pharmaradar360.com/article/la-aemps-actualiza-su-carta-de-servicios-para-el-periodo-2026-2029-4a761197b452f87fPharma Surgeen2026-07-15T08:17:15.000ZLa AEMPS actualiza su Carta de Servicios para el periodo 2026-2029https://www.pharmaradar360.com/article/dutch-innovative-pharma-adding-8-5-billion-to-economy-7817d96798d4c09ePharma Surgeen2026-07-15T08:15:51.000ZDutch innovative pharma adding €8.5 billion to economyhttps://www.pharmaradar360.com/article/attovia-files-for-ipo-to-take-on-sanofi-and-regeneron-s-dupixent-f4d053726a21cbd8Pharma Surgeen2026-07-15T08:09:32.000ZAttovia files for IPO to take on Sanofi and Regeneron’s Dupixenthttps://www.pharmaradar360.com/article/diversify-wealth-management-llc-buys-54-488-shares-of-teva-pharmaceutical-indust-4888447e4cffe6a2Pharma Surgeen2026-07-15T07:52:32.000ZDiversify Wealth Management LLC Buys 54,488 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/i-i-startup-attovia-files-to-go-public-as-biotech-listings-momentum-builds-b612961afb583fb9Pharma Surgeen2026-07-15T07:46:00.000ZI&I startup Attovia files to go public as biotech listings momentum buildshttps://www.pharmaradar360.com/article/biotech-growth-trust-gains-19-2-in-june-outperforms-benchmark-06d44d171ad17184Pharma Surgeen2026-07-15T07:31:27.000ZBiotech Growth Trust Gains 19.2% In June, Outperforms Benchmarkhttps://www.pharmaradar360.com/article/imdylltra-becab08624a27dc1Pharma Surgeen2026-07-15T07:29:38.000ZIMDYLLTRAhttps://www.pharmaradar360.com/article/hemab-s-sutacimig-cuts-bleeds-84-in-phase-2-glanzmann-thrombasthenia-study-3d9d7d9e5d4ec704Pharma Surgeen2026-07-15T07:09:18.000ZHemab’s Sutacimig Cuts Bleeds 84% in Phase 2 Glanzmann Thrombasthenia Studyhttps://www.pharmaradar360.com/article/oric-initiates-himalayas-1-phase-3-trial-of-rinzimetostat-for-mcrpc-4ed4382f0766028fPharma Surgeen2026-07-15T07:09:18.000ZORIC Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat for mCRPChttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-reports-9-7-june-nav-increase-66b94ddac3f25c05Pharma Surgeen2026-07-15T07:03:49.000ZRTW Biotech Opportunities reports 9.7% June NAV increasehttps://www.pharmaradar360.com/article/formulation-freedom-in-clinical-development-why-fill2weight-matters-c2bd55340fe6b99dPharma Surgeen2026-07-15T07:00:38.000ZFormulation freedom in clinical development: Why Fill2Weight mattershttps://www.pharmaradar360.com/article/epoch-biotech-highlights-new-preclinical-data-for-apoe-christchurch-mimetic-anti-4f8bdc03ab40700bPharma Surgeen2026-07-15T07:00:00.000ZEpoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approachhttps://www.pharmaradar360.com/article/kelun-biotech-s-sac-tmt-plus-pembrolizumab-hits-primary-endpoint-in-pd-l1-negati-16c13f87c3493585Pharma Surgeen2026-07-15T06:59:18.000ZKelun-Biotech’s sac-TMT Plus Pembrolizumab Hits Primary Endpoint in PD-L1-Negative NSCLChttps://www.pharmaradar360.com/article/claiming-9-77-billion-yuan-cathay-biotech-launches-large-scale-trade-secret-liti-b96e30c1aad4b3ebPharma Surgeen2026-07-15T06:47:53.000ZClaiming 9.77 billion yuan! Cathay Biotech launches large-scale trade secret litigationhttps://www.pharmaradar360.com/article/reg-rtw-biotech-opp-monthly-valuation-update-and-factsheet-474dfdce6b323116Pharma Surgeen2026-07-15T06:00:00.000ZREG - RTW Biotech Opp. - Monthly Valuation Update and Factsheethttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-maxigen-biotech-inc-twse-1783-c77d94da84761100Pharma Surgeen2026-07-15T05:55:11.000ZEnterprise value to EBITDA forward of Maxigen Biotech Inc. – TWSE:1783https://www.pharmaradar360.com/article/modulis-100-mg-ml-oral-solution-for-dogs-8-1-10-1-588ba073dccf167dPharma Surgeen2026-07-15T05:39:52.000ZΑνάκληση του κτηνιατρικού προϊόντος MODULIS 100 MG/ML ORAL SOLUTION FOR DOGS, με αρ. παρτίδων 8Β1 και 10Β1https://www.pharmaradar360.com/article/development-of-the-regenerative-medicine-product-amchepry-receives-the-10th-japa-a434e5108c8b9549Pharma Surgeen2026-07-15T05:30:00.000ZDevelopment of the Regenerative Medicine Product “AMCHEPRY” Receives the 10th Japan Bioindustry Awardhttps://www.pharmaradar360.com/article/sudan-s-embassy-in-india-hosts-roundtable-on-investment-opportunities-in-pharmac-8ea90beebe7205a6Pharma Surgeen2026-07-15T05:28:01.000ZSudan’s embassy in India hosts roundtable on investment opportunities in pharmaceutical and healthcare sectorshttps://www.pharmaradar360.com/article/from-support-to-success-joeline-moodley-s-career-journey-d8c6abd1ac9e2bb4Pharma Surgeen2026-07-15T05:25:15.000ZFrom Support to Success: Joeline Moodley’s Career Journeyhttps://www.pharmaradar360.com/article/biotech-ipos-surge-in-h1-of-2026-shattering-records-and-doubling-last-year-s-tot-d4bcff34aa0b9126Pharma Surgeen2026-07-15T05:05:29.000ZBiotech IPOs surge in H1 of 2026, shattering records and doubling last year’s totalhttps://www.pharmaradar360.com/article/why-is-tasly-pharmaceutical-stock-rallying-today-a4038067f16901ddPharma Surgeen2026-07-15T05:02:24.000ZWhy is Tasly Pharmaceutical stock rallying today?https://www.pharmaradar360.com/article/fda-grants-priority-review-to-roche-s-gazyva-gazyvaro-for-adults-with-primary-me-eb7e474db9a0bc4fPharma Surgeen2026-07-15T05:00:00.000ZFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathyhttps://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-e94755f97d7a4fbfPharma Surgeen2026-07-15T04:58:19.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jin-yang-pharmaceutical-co-ltd-krx-007370-9526e989f10397a5Pharma Surgeen2026-07-15T03:46:09.000ZEnterprise value to EBIT forward of Jin Yang Pharmaceutical Co., Ltd. – KRX:007370https://www.pharmaradar360.com/article/price-to-earnings-forward-of-jin-yang-pharmaceutical-co-ltd-krx-007370-bc58f1ac9c6307caPharma Surgeen2026-07-15T03:12:11.000ZPrice to earnings forward of Jin Yang Pharmaceutical Co., Ltd. – KRX:007370https://www.pharmaradar360.com/article/spain-signals-new-direction-on-eu-biotech-innovation-3fa4c08cab638405Pharma Surgeen2026-07-15T02:34:31.000ZSpain signals new direction on EU biotech innovationhttps://www.pharmaradar360.com/article/maha-fda-cracks-down-on-blood-centres-suspends-34-licences-and-cancels-4-for-vio-350ea48ed20826f5Pharma Surgeen2026-07-15T02:32:09.000ZMaha FDA cracks down on blood centres, suspends 34 licences and cancels 4 for violating drug normshttps://www.pharmaradar360.com/article/study-supports-onconic-s-jaqbo-co-use-with-common-cardiovascular-drugs-0e4d0db984bb3e24Pharma Surgeen2026-07-15T02:25:51.000ZStudy supports Onconic's Jaqbo co-use with common cardiovascular drugshttps://www.pharmaradar360.com/article/celltrion-ends-european-keytruda-biosimilar-trial-d9d7f6d3242fe33bPharma Surgeen2026-07-15T02:09:09.000ZCelltrion Ends European Keytruda Biosimilar Trialhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-enters-strategic-agreements-w-5895a90248a2b38cPharma Surgeen2026-07-15T01:27:26.000ZWest Pharmaceutical Services (WST) Enters Strategic Agreements whttps://www.pharmaradar360.com/article/fda-lets-leqembi-start-at-home-with-15-second-subcutaneous-shots-chosunbiz-69ff5749f795c132Pharma Surgeen2026-07-15T01:20:00.000ZFDA lets Leqembi start at home with 15-second subcutaneous shots - CHOSUNBIZhttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-too-expensive-after-a-440-return-e46fb525191e6938Pharma Surgeen2026-07-15T01:02:24.000ZIs Krystal Biotech (KRYS) Too Expensive After A 440% Return?https://www.pharmaradar360.com/article/fda-clears-atrium-therapeutics-ind-application-for-cardiomyopathy-drug-057d8eeeec7a2cd9Pharma Surgeen2026-07-15T00:35:37.000ZFDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drughttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-advances-tev-408-is-the-stock-still-cheap-5afbbc442799b8edPharma Surgeen2026-07-15T00:16:28.000ZTeva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/taiho-pharmaceutical-announces-the-launch-of-pi3k-inhibitor-haizexin-tablets-10m-baa20d4788ae076bPharma Surgeen2026-07-15T00:00:00.000ZTaiho Pharmaceutical Announces the Launch of PI3Kα Inhibitor HAIZEXIN® Tablets 10mg in Japanhttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-07-15T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-c4e95f58a9dbd80fPharma Surgeen2026-07-15T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-0fb0493ec3b1b472Pharma Surgeen2026-07-15T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-88d6731c3f7000e8Pharma Surgeen2026-07-15T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-10367a0c6e41366ePharma Surgeen2026-07-15T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-7a96393e54361fc3Pharma Surgeen2026-07-15T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-cdd057602c632224Pharma Surgeen2026-07-15T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-12947dd97babb2e1Pharma Surgeen2026-07-15T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a2af2fd10ee234aaPharma Surgeen2026-07-15T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-75dab0ebd0d1d1b1Pharma Surgeen2026-07-15T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-10090283897cdeeePharma Surgeen2026-07-15T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e859568aea77dbe9Pharma Surgeen2026-07-15T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-ae2ca742f93fe44dPharma Surgeen2026-07-15T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-9af036c1711c8eaaPharma Surgeen2026-07-15T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6625d91ce9754161Pharma Surgeen2026-07-15T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-institute-on-minority-health-and-health-disparities-notice-of-partially-c5a456fd0485629cPharma Surgeen2026-07-15T00:00:00.000ZNational Institute on Minority Health and Health Disparities; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-f447794c7efab6fdPharma Surgeen2026-07-15T00:00:00.000ZCenter For Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-office-of-refugee-resettle-167423eea5e86981Pharma Surgeen2026-07-15T00:00:00.000ZSubmission for Office of Management and Budget Review; Office of Refugee Resettlement Unaccompanied Refugee Minors Program Application and Withdrawal of Unaccompanied Refugee Minors Program Application or Declination of Unaccompanied Refugee Minors Program Placement Formshttps://www.pharmaradar360.com/article/meetings-of-the-presidential-advisory-council-on-combating-antibiotic-resistant-756fbe52bcde29c3Pharma Surgeen2026-07-15T00:00:00.000ZMeetings of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteriahttps://www.pharmaradar360.com/article/request-for-information-rfi-inviting-comments-and-suggestions-on-topic-areas-for-d57f08eae827135bPharma Surgeen2026-07-15T00:00:00.000ZRequest for Information (RFI): Inviting Comments and Suggestions on Topic Areas for the NIDCR Strategic Plan for Fiscal Years 2027-2031https://www.pharmaradar360.com/article/drug-label-update-acetaminophen-extra-strength-cd3f3091fa2d9e7ePharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Acetaminophen Extra Strengthhttps://www.pharmaradar360.com/article/drug-label-update-allergy-relief-d593cd0779dcd03aPharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Allergy Reliefhttps://www.pharmaradar360.com/article/mandibular-idiopathic-osteosclerosis-mimicking-inferior-alveolar-nerve-conflict-44da4b97368ffc21Pharma Surgeen2026-07-15T00:00:00.000ZMandibular idiopathic osteosclerosis mimicking inferior alveolar nerve conflicthttps://www.pharmaradar360.com/article/response-to-letter-to-editor-a-randomized-clinical-trial-with-unresolved-data-in-515192cbd5772e4fPharma Surgeen2026-07-15T00:00:00.000ZResponse to letter to editor: a randomized clinical trial with unresolved data integrity concernshttps://www.pharmaradar360.com/article/bilateral-pulmonary-arteriovenous-fistulas-in-a-young-patient-with-ischemic-stro-e1fa94b2c4913e14Pharma Surgeen2026-07-15T00:00:00.000ZBilateral Pulmonary Arteriovenous Fistulas in A Young Patient with Ischemic Stroke: A Case Reporthttps://www.pharmaradar360.com/article/beyond-the-classical-approach-successful-sequential-ablation-of-fast-slow-and-sl-23f3e85fdae22ad3Pharma Surgeen2026-07-15T00:00:00.000ZBeyond the Classical Approach: Successful Sequential Ablation of Fast-Slow and Slow-Fast Atrioventricular Nodal Reentrant Tachycardia. An Illustrative Casehttps://www.pharmaradar360.com/article/development-and-clinical-application-of-an-ultrasound-based-deep-learning-model-526753732ac16f94Pharma Surgeen2026-07-15T00:00:00.000ZDevelopment and clinical application of an ultrasound-based deep learning model for preoperative staging of colorectal cancerhttps://www.pharmaradar360.com/article/incidents-related-to-brachytherapy-in-the-united-states-over-the-last-10-years-68ee34ab90d3915cPharma Surgeen2026-07-15T00:00:00.000ZIncidents Related to Brachytherapy in the United States over the Last 10 Yearshttps://www.pharmaradar360.com/article/personalized-treatment-of-the-non-responder-population-the-biggest-unmet-clinica-cc75afba0d915271Pharma Surgeen2026-07-15T00:00:00.000ZPersonalized treatment of the non-responder population: The biggest unmet clinical demand in precision medicinehttps://www.pharmaradar360.com/article/feasibility-and-acceptability-of-a-group-based-telehealth-stress-management-and-373e278837b7dbaePharma Surgeen2026-07-15T00:00:00.000ZFeasibility and Acceptability of a Group-Based Telehealth Stress Management and Resilience Training Intervention for Men with Prostate Cancer on Active Surveillancehttps://www.pharmaradar360.com/article/association-between-systolic-blood-pressure-at-emergency-department-arrival-and-bfd76143da0a4bc9Pharma Surgeen2026-07-15T00:00:00.000ZAssociation Between Systolic Blood Pressure at Emergency Department Arrival and Time to Bleeding Cessation in Adult Non-Traumatic Epistaxis: A Retrospective Time-to-Event Analysishttps://www.pharmaradar360.com/article/analysis-and-implications-of-validation-results-for-a-clinical-data-based-early-c22ad35452bb9bc2Pharma Surgeen2026-07-15T00:00:00.000ZAnalysis and implications of validation results for a clinical data-based early warning model for geriatric sepsishttps://www.pharmaradar360.com/article/editorial-unlocking-cancer-s-secrets-overcoming-drug-resistance-in-cancer-stem-c-bc083b581b9775afPharma Surgeen2026-07-15T00:00:00.000ZEditorial: Unlocking cancer’s secrets: overcoming drug resistance in cancer stem cellshttps://www.pharmaradar360.com/article/drug-tolerant-persister-cells-in-lymphoid-malignancies-from-mechanisms-to-therap-e90160dd027aaacbPharma Surgeen2026-07-15T00:00:00.000ZDrug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunitieshttps://www.pharmaradar360.com/article/clinical-phenotype-identification-based-on-inflammation-nutrition-coagulation-bi-eb1ae39074811d90Pharma Surgeen2026-07-15T00:00:00.000ZClinical phenotype identification based on inflammation–nutrition–coagulation biomarkers in advanced non-small cell lung cancerhttps://www.pharmaradar360.com/article/fourier-transform-infrared-spectroscopy-with-machine-learning-for-rapid-o-serogr-23e21c7f1a79407fPharma Surgeen2026-07-15T00:00:00.000ZFourier-transform infrared spectroscopy with machine learning for rapid O-serogrouping and typhi differentiation of clinical Salmonella isolateshttps://www.pharmaradar360.com/article/development-and-clinical-validation-of-an-artificial-intelligence-based-model-fo-e2e1fa9b121cbe42Pharma Surgeen2026-07-15T00:00:00.000ZDevelopment and clinical validation of an artificial intelligence based model for thyroid nodule malignancy risk assessment using C-TIRADS guidelineshttps://www.pharmaradar360.com/article/effect-of-tegileridine-pretreatment-on-fentanyl-induced-cough-during-general-ane-411da8f9bbcd1c4ePharma Surgeen2026-07-15T00:00:00.000ZEffect of tegileridine pretreatment on fentanyl-induced cough during general anesthesia induction: a randomized controlled trialhttps://www.pharmaradar360.com/article/diagnostic-accuracy-and-clinical-performance-of-deep-learning-models-for-grading-e554950e9894ca65Pharma Surgeen2026-07-15T00:00:00.000ZDiagnostic accuracy and clinical performance of deep learning models for grading diabetic retinopathy: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/from-bench-to-bowel-translating-targeted-drug-delivery-through-gastrointestinal-19d9c4f47c29ce7aPharma Surgeen2026-07-15T00:00:00.000ZFrom bench to bowel: translating targeted drug delivery through gastrointestinal barriershttps://www.pharmaradar360.com/article/pathogenetic-significance-of-b-lymphocytes-in-various-clinical-forms-of-urogenit-31d7c04f69515980Pharma Surgeen2026-07-15T00:00:00.000ZPathogenetic Significance of B-Lymphocytes in Various Clinical Forms of Urogenital Reactive Arthritishttps://www.pharmaradar360.com/article/combined-maxillofacial-and-craniocerebral-injuries-clinical-and-statistical-anal-5ae6dabba652e0c6Pharma Surgeen2026-07-15T00:00:00.000ZCombined Maxillofacial and Craniocerebral Injuries: Clinical and Statistical Analysis and Optimization of Treatmenthttps://www.pharmaradar360.com/article/peripheral-blood-cell-counts-of-prematurely-born-small-for-gestational-age-neona-9d69f3dcb4d19ab4Pharma Surgeen2026-07-15T00:00:00.000ZPeripheral blood cell counts of prematurely born, small for gestational age neonateshttps://www.pharmaradar360.com/article/healthcare-associated-mycobacterial-port-site-infections-following-laparoscopic-b6382652751fd380Pharma Surgeen2026-07-15T00:00:00.000ZHealthcare-Associated Mycobacterial Port-Site Infections Following Laparoscopic Surgery: Clinical Characteristics and Epidemiological Evidence from a Multicenter Cohort in Bangladeshhttps://www.pharmaradar360.com/article/application-of-minics-software-in-measuring-parameters-of-femoral-neck-fractures-6512b4aa419d8983Pharma Surgeen2026-07-15T00:00:00.000ZApplication of MINICS software in measuring parameters of femoral neck fractures and its clinical significancehttps://www.pharmaradar360.com/article/retrospective-comparative-analysis-of-diffusion-tensor-and-constrained-spherical-cc7877f9a0b5e66cPharma Surgeen2026-07-15T00:00:00.000ZRetrospective Comparative Analysis of Diffusion Tensor and Constrained Spherical Deconvolution Tractography Models in a Clinical Neurosurgical Navigation Platformhttps://www.pharmaradar360.com/article/a-novel-ferro-aging-related-gene-signature-for-prognosis-and-targeted-drug-predi-355553a15cb2fb93Pharma Surgeen2026-07-15T00:00:00.000ZA Novel Ferro-Aging-Related Gene Signature for Prognosis and Targeted Drug Prediction in Cervical Cancerhttps://www.pharmaradar360.com/article/microbiota-transplant-therapy-mtt-improves-gastrointestinal-symptoms-in-children-3f76d1d66fb8510ePharma Surgeen2026-07-15T00:00:00.000ZMicrobiota Transplant Therapy (MTT) Improves Gastrointestinal Symptoms in Children with Pitt-Hopkins Syndrome: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/lar-net-a-lightweight-adaptive-receptive-field-network-for-point-cloud-segmentat-fbaa6e598ab5eb78Pharma Surgeen2026-07-15T00:00:00.000ZLAR-Net: A Lightweight Adaptive Receptive Field Network for Point Cloud Segmentation of Pharmaceutical Deposits on Reactor Inner Wallshttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-between-femtosecond-laser-assisted-cataract-surg-f12b5de3f137a93aPharma Surgeen2026-07-15T00:00:00.000ZComparison of Clinical Outcomes Between Femtosecond Laser-assisted Cataract Surgery and Phacoemulsification in Patients with Diabetes: A Systematic Reviewhttps://www.pharmaradar360.com/article/allergic-rhinitis-in-clinical-practice-epidemiology-diagnosis-burden-and-contemp-cb24b7f6b9a7aaaePharma Surgeen2026-07-15T00:00:00.000ZAllergic rhinitis in clinical practice: Epidemiology, diagnosis, burden, and contemporary management in otorhinolaryngologyhttps://www.pharmaradar360.com/article/comparison-of-trough-only-and-peak-trough-concentration-data-for-the-calculation-094d2298f211a9fdPharma Surgeen2026-07-15T00:00:00.000ZComparison of Trough-Only and Peak–Trough Concentration Data for the Calculation of Vancomycin Area under the Concentration–Time Curve on Day 2 Using Previous and Updated Population Pharmacokinetic Modelshttps://www.pharmaradar360.com/article/temporal-changes-in-clinical-practice-and-mortality-in-aneurysmal-subarachnoid-h-daeb2ac01515c803Pharma Surgeen2026-07-15T00:00:00.000ZTemporal changes in clinical practice and mortality in aneurysmal subarachnoid hemorrhage following the 2012 AHA/ASA guidelines: a retrospective cohort study using the MIMIC databasehttps://www.pharmaradar360.com/article/histone-lysine-methyltransferases-kmt2c-and-kmt2d-join-the-all-star-tumor-suppre-f7dfd7c61e5d7e88Pharma Surgeen2026-07-15T00:00:00.000ZHistone lysine methyltransferases KMT2C and KMT2D join the all-star tumor suppressor team in gastrointestinal cancerhttps://www.pharmaradar360.com/article/targeting-hepatic-cholesterol-sensing-to-tackle-metabolic-dysfunction-associated-5b3618c89b2f06cdPharma Surgeen2026-07-15T00:00:00.000ZTargeting hepatic cholesterol sensing to tackle metabolic dysfunction–associated steatohepatitishttps://www.pharmaradar360.com/article/gut-microbe-derived-short-chain-fatty-acids-regulate-alphavirus-arthritis-and-ma-de7de1f1051b2880Pharma Surgeen2026-07-15T00:00:00.000ZGut microbe–derived short-chain fatty acids regulate alphavirus arthritis and macrophage activation in micehttps://www.pharmaradar360.com/article/branched-chain-amino-acid-metabolism-and-microbiome-in-adolescents-with-obesity-d9f9c355c1db3589Pharma Surgeen2026-07-15T00:00:00.000ZBranched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapyhttps://www.pharmaradar360.com/article/figure-3-from-car-t-cell-kinetics-persistence-and-clinical-outcomes-in-adult-pat-3d0904d8caff3470Pharma Surgeen2026-07-15T00:00:00.000ZFigure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/figure-5-from-car-t-cell-kinetics-persistence-and-clinical-outcomes-in-adult-pat-f77ba97c7bce08d1Pharma Surgeen2026-07-15T00:00:00.000ZFigure 5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/supplementary-table-s3-from-car-t-cell-kinetics-persistence-and-clinical-outcome-fde6a3539eccd0b2Pharma Surgeen2026-07-15T00:00:00.000ZSupplementary Table S3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/supplementary-table-s6-from-car-t-cell-kinetics-persistence-and-clinical-outcome-c8951be6c287e311Pharma Surgeen2026-07-15T00:00:00.000ZSupplementary Table S6 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/enhancing-clinical-diagnosis-of-amyotrophic-lateral-sclerosis-through-advanced-p-7f2028da2c685acdPharma Surgeen2026-07-15T00:00:00.000ZEnhancing Clinical Diagnosis of Amyotrophic Lateral Sclerosis Through Advanced Prediction and Analysis Using Deep Learninghttps://www.pharmaradar360.com/article/a-retrospective-cohort-study-on-clinical-presentation-and-surgical-management-of-be018f3836cf4a57Pharma Surgeen2026-07-15T00:00:00.000ZA retrospective cohort study on clinical presentation and surgical management of rectal prolapse at a tertiary care centerhttps://www.pharmaradar360.com/article/comment-on-the-reliability-and-smallest-detectable-difference-of-the-severity-of-e4c1c35e6de5bfebPharma Surgeen2026-07-15T00:00:00.000ZComment on ‘The reliability and smallest detectable difference of the Severity of Alopecia Tool score in alopecia areata’https://www.pharmaradar360.com/article/effectiveness-and-cost-effectiveness-of-digital-approaches-for-training-frontlin-d9cdf4f6c4902c6fPharma Surgeen2026-07-15T00:00:00.000ZEffectiveness and cost-effectiveness of digital approaches for training frontline health workers in depression care: a randomized controlled trialhttps://www.pharmaradar360.com/article/pharmaceutical-cocrystals-of-febuxostat-design-fabrication-characterization-and-c9e0ffc66c926544Pharma Surgeen2026-07-15T00:00:00.000ZPharmaceutical Cocrystals of Febuxostat: Design, Fabrication, Characterization and Bioavailability Assessmenthttps://www.pharmaradar360.com/article/plant-growth-promotion-of-rice-oryza-sativa-l-with-root-endophytic-bacteria-isol-536af6b7e134ac3cPharma Surgeen2026-07-15T00:00:00.000ZPlant growth promotion of rice (Oryza sativa L.) with root endophytic bacteria, isolated from wild Solanaceous medicinal plants Solanum nigrum L., Solanum sisymbriifolium Lam., and Solanum virginianum L.https://www.pharmaradar360.com/article/microbial-inoculation-enhances-salt-tolerance-by-modulating-secondary-metabolite-b8a6050b368f862aPharma Surgeen2026-07-15T00:00:00.000ZMicrobial inoculation enhances salt tolerance by modulating secondary metabolites and key biosynthetic genes in Melissa officinalishttps://www.pharmaradar360.com/article/matrine-suppresses-thymoma-stemness-and-apoptosis-via-yth-n6-methyladenosine-rna-c94e4de681d1dac9Pharma Surgeen2026-07-15T00:00:00.000ZMatrine suppresses thymoma stemness and apoptosis via YTH N6-methyladenosine RNA binding protein 1 and Wnt/β-catenin signalinghttps://www.pharmaradar360.com/article/her2-positive-rectal-adenocarcinoma-metastatic-to-the-pancreas-complicated-by-ob-85892179bf8ec779Pharma Surgeen2026-07-15T00:00:00.000ZHER2-positive rectal adenocarcinoma metastatic to the pancreas complicated by obstructive pancreatitis and an infected pseudocyst: a case reporthttps://www.pharmaradar360.com/article/agrp-reflects-glucocorticoid-action-integrated-experimental-and-clinical-evidenc-1e2ce43c1e8f1f99Pharma Surgeen2026-07-15T00:00:00.000ZAgRP reflects glucocorticoid action: integrated experimental and clinical evidencehttps://www.pharmaradar360.com/article/the-apelin-apj-axis-in-heart-failure-mechanistic-insights-clinical-evidence-and-7411cb6629142213Pharma Surgeen2026-07-15T00:00:00.000ZThe Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challengeshttps://www.pharmaradar360.com/article/real-world-evaluation-of-primary-prophylactic-use-of-granulocyte-colony-stimulat-77067d0759237640Pharma Surgeen2026-07-15T00:00:00.000ZReal-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapyhttps://www.pharmaradar360.com/article/correlation-between-mri-disc-morphology-and-temporomandibular-joint-osteoarthrit-d3c85bb45d1b8af4Pharma Surgeen2026-07-15T00:00:00.000ZCorrelation between MRI disc morphology and temporomandibular joint osteoarthritis in patients with temporomandibular joint disc displacement with reduction: a cross-sectional CBCT-MRI combined studyhttps://www.pharmaradar360.com/article/letter-to-the-editor-re-deep-learning-models-for-lumbar-spinal-stenosis-on-mri-m-0a0820ce9e4b5321Pharma Surgeen2026-07-15T00:00:00.000ZLetter to the Editor Re: “Deep learning models for lumbar spinal stenosis on MRI: model comparison and clinical benchmarking” by Lee et al. (Eur Spine J [2026] 35:548–558. DOI: 10.1007/s00586-025-09443-2)https://www.pharmaradar360.com/article/a-misaligned-multi-modal-clinical-time-series-representation-learning-framework-d6de250d3492a962Pharma Surgeen2026-07-15T00:00:00.000ZA Misaligned Multi-modal Clinical Time Series Representation Learning Framework for In-Hospital Mortality Predictionhttps://www.pharmaradar360.com/article/ugca-dti-uncertainty-gated-cross-attention-for-robust-drug-target-interaction-pr-b9deafb6c9e3303bPharma Surgeen2026-07-15T00:00:00.000ZUGCA-DTI: Uncertainty-Gated Cross-Attention for Robust Drug–Target Interaction Predictionhttps://www.pharmaradar360.com/article/an-interactive-web-server-for-multi-model-drug-repositioning-and-evidence-tracin-604d01fe2cff5a73Pharma Surgeen2026-07-15T00:00:00.000ZAn Interactive Web Server for Multi-model Drug Repositioning and Evidence Tracinghttps://www.pharmaradar360.com/article/predicting-drug-synergy-via-cross-modal-contrastive-learning-and-masked-multi-om-16216e23fd710908Pharma Surgeen2026-07-15T00:00:00.000ZPredicting Drug Synergy via Cross-modal Contrastive Learning and Masked Multi-omics Hypergraphshttps://www.pharmaradar360.com/article/the-expression-patterns-of-antibody-drug-conjugate-related-markers-in-urothelial-00b0c48e66cfe232Pharma Surgeen2026-07-15T00:00:00.000ZThe Expression Patterns of Antibody–Drug Conjugate‐Related Markers in Urothelial Carcinoma With Histological Variantshttps://www.pharmaradar360.com/article/anatomy-curriculum-and-teaching-insights-from-medical-students-in-the-united-kin-fc561d126754ce3fPharma Surgeen2026-07-15T00:00:00.000ZAnatomy Curriculum and Teaching Insights From Medical Students in the United Kingdom: A National Surveyhttps://www.pharmaradar360.com/article/otsuka-group-introduces-its-first-battery-energy-storage-system-in-hokkaido-aims-a6dabe7ee5ababa0Pharma Surgeen2026-07-15T00:00:00.000ZOtsuka Group Introduces Its First Battery Energy Storage System in Hokkaido —Aims to Maximize Renewable Energy Use and Stabilize Power Supply in Order to Promote Business Growth and Environmental Initiatives—https://www.pharmaradar360.com/article/erasca-eras-surges-8-9-on-encouraging-cancer-trial-results-c588ba98a6e05dd8Pharma Surgeen2026-07-14T23:40:45.000ZErasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Resultshttps://www.pharmaradar360.com/article/kelun-biotech-announces-phase-iii-study-of-sacituzumab-tirumotecan-sac-tmt-in-co-7ba056ff9e7e079fPharma Surgeen2026-07-14T23:30:00.000ZKelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpointhttps://www.pharmaradar360.com/article/dothan-named-hub-for-15m-biotech-project-cdde5d84ccd9cc25Pharma Surgeen2026-07-14T22:57:32.000ZDothan Named Hub for $15M Biotech Projecthttps://www.pharmaradar360.com/article/asu-callan-jmb-partner-to-boost-alabama-s-workforce-and-pharmaceutical-industry-c5db822667ceb8bdPharma Surgeen2026-07-14T22:47:07.000ZASU, Callan JMB Partner to Boost Alabama’s Workforce and Pharmaceutical Industryhttps://www.pharmaradar360.com/article/lessons-learned-on-commercializing-an-allogeneic-t-cell-therapy-202f2c37220690baPharma Surgeen2026-07-14T22:16:45.000ZLessons Learned on Commercializing an Allogeneic T Cell Therapyhttps://www.pharmaradar360.com/article/becky-jackson-curran-advocates-for-accessibility-and-understanding-b775105ac7d94180Pharma Surgeen2026-07-14T20:53:32.000ZBecky Jackson Curran Advocates for Accessibility and Understandinghttps://www.pharmaradar360.com/article/invesco-healthcare-etf-vs-vaneck-biotech-which-etf-will-deliver-the-healthiest-r-3339ce11d3479df4Pharma Surgeen2026-07-14T20:41:00.000ZInvesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?https://www.pharmaradar360.com/article/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-c54d18e356d798dfPharma Surgeen2026-07-14T20:26:44.000ZORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayerhttps://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64Pharma Surgeen2026-07-14T20:14:42.000ZDrug Alerts and Statementshttps://www.pharmaradar360.com/article/petition-asks-fda-to-implement-new-oem-rule-for-mri-safety-35caf55636450b44Pharma Surgeen2026-07-14T20:11:48.000ZPetition asks FDA to implement new OEM rule for MRI safetyhttps://www.pharmaradar360.com/article/bayer-will-provide-nubeqa-at-no-cost-for-oric-s-global-trial-448b8f0cde54dc6aPharma Surgeen2026-07-14T20:05:00.000ZBayer Will Provide NUBEQA at No Cost for ORIC’s Global Trialhttps://www.pharmaradar360.com/article/vivani-medical-to-present-at-the-emerging-growth-conference-on-july-15-2026-3fd8ddf5f4e54deePharma Surgeen2026-07-14T20:03:00.000ZVivani Medical to Present at the Emerging Growth Conference on July 15, 2026https://www.pharmaradar360.com/article/potential-first-in-class-treatment-for-scd-awarded-fda-priority-review-aa98ef10b58013acPharma Surgeen2026-07-14T19:45:33.000ZPotential first-in-class treatment for SCD awarded FDA priority reviewhttps://www.pharmaradar360.com/article/bar-ilan-university-and-sheba-medical-center-joining-forces-for-biotech-innovati-e3c850f71c022ac1Pharma Surgeen2026-07-14T19:41:41.000ZBar-Ilan University and Sheba Medical Center Joining Forces for Biotech Innovation Institute With $120 Million Investmenthttps://www.pharmaradar360.com/article/what-s-the-status-of-house-lawmakers-bill-on-china-biotech-restrictions-72755b41f1426b68Pharma Surgeen2026-07-14T19:41:00.000ZWhat’s the status of House lawmakers’ bill on China biotech restrictions?https://www.pharmaradar360.com/article/momentum-will-continue-in-the-biotech-sector-says-mizuho-s-jared-holz-5f69cd16c60614d8Pharma Surgeen2026-07-14T19:24:05.000ZMomentum will continue in the biotech sector, says Mizuho's Jared Holzhttps://www.pharmaradar360.com/article/fda-grants-traditional-approval-to-selpercatinib-for-ret-fusion-solid-tumors-0164333a4d547a9fPharma Surgeen2026-07-14T19:15:06.000ZFDA Grants Traditional Approval to Selpercatinib for RET-Fusion Solid Tumorshttps://www.pharmaradar360.com/article/post-hoc-live-what-s-making-biotech-ipos-work-again-efae51883ef57b47Pharma Surgeen2026-07-14T18:31:00.000ZPost-Hoc Live: What’s making biotech IPOs work again?https://www.pharmaradar360.com/article/the-blueprint-for-a-bigger-medical-bureaucracy-news-article-cdd94d648bd78aaePharma Surgeen2026-07-14T18:30:37.000ZThe Blueprint for a Bigger Medical Bureaucracy: News Articlehttps://www.pharmaradar360.com/article/fda-finalizes-psychedelic-trial-rules-unblinding-problem-gets-official-answer-325406f464e5701cPharma Surgeen2026-07-14T18:21:50.000ZFDA Finalizes Psychedelic Trial Rules: Unblinding Problem Gets Official Answerhttps://www.pharmaradar360.com/article/fda-approves-subcutaneous-formulation-of-leqembi-iqlik-pharmexec-eb20eec74de4163bPharma Surgeen2026-07-14T18:17:38.000ZFDA Approves Subcutaneous Formulation of Leqembi Iqlik | PharmExechttps://www.pharmaradar360.com/article/penny-for-your-thoughts-episode-14-b23eff2f5420f0c4Pharma Surgeen2026-07-14T18:04:09.000ZPenny for Your Thoughts: Episode 14https://www.pharmaradar360.com/article/biogen-defends-anti-tau-drug-after-stock-slides-on-alzheimer-s-readout-50a57927ddd229d5Pharma Surgeen2026-07-14T18:00:18.000ZBiogen defends anti-tau drug after stock slides on Alzheimer’s readouthttps://www.pharmaradar360.com/article/spero-therapeutics-buy-utebzi-royalty-deal-for-funding-and-sp001-in-licensing-sp-5dfc5554633ba68aPharma Surgeen2026-07-14T17:40:33.000ZSpero Therapeutics: "Buy" Utebzi Royalty Deal For Funding And SP001 In-Licensing (SPRO)https://www.pharmaradar360.com/article/fda-suspends-licences-of-three-mumbai-hotels-over-serious-food-safety-violations-f3d7ad9085a210ccPharma Surgeen2026-07-14T17:24:00.000ZFDA suspends licences of three Mumbai hotels over serious food safety violationshttps://www.pharmaradar360.com/article/q-a-what-will-it-take-to-reshore-us-drug-manufacturing-025ebcadf010b0ccPharma Surgeen2026-07-14T17:04:38.000ZQ&A: What Will It Take to Reshore US Drug Manufacturing?https://www.pharmaradar360.com/article/judge-orders-apple-tree-partner-to-forfeit-oversight-of-venture-fund-9aeb89d7303db145Pharma Surgeen2026-07-14T16:27:53.000ZJudge orders Apple Tree partner to forfeit oversight of venture fundhttps://www.pharmaradar360.com/article/data-is-the-new-commodity-while-the-surgical-robot-is-the-true-enabler-of-the-ne-de8fe4279f1f9ec7Pharma Surgeen2026-07-14T16:23:06.000ZData is the New Commodity, While the Surgical Robot is the True Enabler of the New Economyhttps://www.pharmaradar360.com/article/the-unapproved-but-very-online-weight-loss-drug-3df017d2ac34f893Pharma Surgeen2026-07-14T16:00:00.000ZThe unapproved but very online weight-loss drughttps://www.pharmaradar360.com/article/fda-outlines-process-for-for-oil-safety-after-recall-9573e7ae75713766Pharma Surgeen2026-07-14T16:00:00.000ZFDA outlines process for for oil safety after recallhttps://www.pharmaradar360.com/article/the-product-that-s-helping-my-blowout-survive-a-new-york-summer-ae9f2471b8bf6676Pharma Surgeen2026-07-14T15:58:18.000ZThe Product That’s Helping My Blowout Survive a New York Summerhttps://www.pharmaradar360.com/article/cordis-project-health-active-responsive-materials-development-stability-safety-a-bf4ed37261c96c41Pharma Surgeen2026-07-14T15:54:03.000ZCORDIS project: Health-Active Responsive Materials: Development, Stability, Safety, and Fate Evaluation in Complex Biological Mediahttps://www.pharmaradar360.com/article/cordis-project-exploring-genetic-resource-of-wild-rice-species-for-neo-domestica-f37c6a4f18c02901Pharma Surgeen2026-07-14T15:50:44.000ZCORDIS project: Exploring Genetic Resource of Wild Rice Species for Neo-domesticationhttps://www.pharmaradar360.com/article/lumacina-appoints-gary-bird-as-ceo-to-accelerate-growth-and-expand-global-steril-51516cd316dcb7b4Pharma Surgeen2026-07-14T15:47:00.000ZLumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfoliohttps://www.pharmaradar360.com/article/fda-finalises-psychedelic-clinical-trial-guidance-c4d6473a3a2fc318Pharma Surgeen2026-07-14T15:43:39.000ZFDA finalises psychedelic clinical trial guidancehttps://www.pharmaradar360.com/article/ministerial-group-for-digital-inclusion-terms-of-reference-64906e0769be48c1Pharma Surgeen2026-07-14T15:43:35.000ZMinisterial Group for Digital Inclusion: terms of referencehttps://www.pharmaradar360.com/article/ministerial-group-for-digital-inclusion-meeting-summaries-b5eb71c24a4b63a9Pharma Surgeen2026-07-14T15:43:31.000ZMinisterial Group for Digital Inclusion: meeting summarieshttps://www.pharmaradar360.com/article/the-u-s-just-approved-a-giant-space-mirror-to-test-sunlight-on-demand-low-earth-9ca5ffd8068e7672Pharma Surgeen2026-07-14T15:38:23.000ZThe U.S. just approved a giant space mirror to test ‘sunlight on demand.’ Low Earth orbit is getting weirdhttps://www.pharmaradar360.com/article/biotech-s-recovery-isn-t-a-head-fake-these-3-stocks-could-lead-the-next-leg-up-8e1beca420654419Pharma Surgeen2026-07-14T15:34:23.000ZBiotech's recovery isn't a 'head fake.' These 3 stocks could lead the next leg uphttps://www.pharmaradar360.com/article/south-korea-s-bio-pharmaceutical-exports-reach-record-4-5-billion-06bd9c6946758cd3Pharma Surgeen2026-07-14T15:32:58.000ZSouth Korea's Bio-Pharmaceutical Exports Reach Record $4.5 Billionhttps://www.pharmaradar360.com/article/new-biotech-avere-plots-listing-via-nextcure-merger-ee80ae17d1699cd8Pharma Surgeen2026-07-14T15:32:51.000ZNew biotech Avere plots listing via NextCure mergerhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-discloses-transactions-with-avere-therapeutics-eba479018ee4f4d6Pharma Surgeen2026-07-14T15:26:44.000ZHansoh Pharmaceutical Discloses Transactions With Avere Therapeuticshttps://www.pharmaradar360.com/article/biotech-news-from-around-the-world-d4aadca984204ddcPharma Surgeen2026-07-14T15:24:58.000ZBiotech news from around the worldhttps://www.pharmaradar360.com/article/pharmaceutical-waste-outreach-program-6075948888daa031Pharma Surgeen2026-07-14T15:21:02.000ZPharmaceutical Waste Outreach Programhttps://www.pharmaradar360.com/article/notifications-on-data-integrity-8f0694aefbbd1a22Pharma Surgeen2026-07-14T15:20:41.000ZNotifications on Data Integrityhttps://www.pharmaradar360.com/article/astrazeneca-pays-up-to-1-5bn-to-license-dizal-pharma-s-lung-cancer-drug-7352fa87037eec86Pharma Surgeen2026-07-14T15:19:53.000ZAstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drughttps://www.pharmaradar360.com/article/the-operational-cost-of-we-ll-add-that-later-7c5644d5f37e6186Pharma Surgeen2026-07-14T15:12:34.000ZThe Operational Cost of “We’ll Add That Later”https://www.pharmaradar360.com/article/vacaciones-de-invierno-en-la-biblioteca-publica-7d7618c79a71d883Pharma Surgeen2026-07-14T15:11:19.000ZVacaciones de Invierno en la Biblioteca Públicahttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-teatro-unlp-c6a9638039d74534Pharma Surgeen2026-07-14T15:08:45.000ZVacaciones de Invierno en el Teatro UNLPhttps://www.pharmaradar360.com/article/dhsc-equality-information-106367862a1bd170Pharma Surgeen2026-07-14T15:07:31.000ZDHSC equality informationhttps://www.pharmaradar360.com/article/ems-investe-no-mercado-fitoterapico-parainsonia-com-a-marca-sominex-e-lanca-camp-551c8cc2ee56110ePharma Surgeen2026-07-14T15:04:52.000ZEMS investe no mercado fitoterápico parainsônia com a marca Sominex e lança campanha exclusiva com ações inéditas na TVhttps://www.pharmaradar360.com/article/5-early-career-faculty-win-2026-hettleman-prizes-987490657e3c0d68Pharma Surgeen2026-07-14T15:04:23.000Z5 early-career faculty win 2026 Hettleman Prizeshttps://www.pharmaradar360.com/article/dhsc-equality-information-2025-8be8df30649a6a71Pharma Surgeen2026-07-14T15:03:59.000ZDHSC equality information: 2025https://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-centro-de-arte-unlp-5d2512de6e8ce047Pharma Surgeen2026-07-14T15:00:14.000ZVacaciones de Invierno en el Centro de Arte UNLPhttps://www.pharmaradar360.com/article/dr-s-leigh-verbois-named-chief-executive-officer-of-rx-360-d16984b7fc10e300Pharma Surgeen2026-07-14T15:00:00.000ZDr. S. Leigh Verbois Named Chief Executive Officer of Rx-360https://www.pharmaradar360.com/article/us-sunscreens-just-got-more-effective-bu-dermatologist-explains-why-fa2c624c36668dd0Pharma Surgeen2026-07-14T15:00:00.000ZUS Sunscreens Just Got More Effective. BU Dermatologist Explains Whyhttps://www.pharmaradar360.com/article/cannara-biotech-lands-a-first-long-term-export-supply-deal-393da85c73c0e877Pharma Surgeen2026-07-14T14:58:25.000ZCannara Biotech Lands A First Long-Term Export Supply Dealhttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-museo-de-quimica-y-farmacia-1c2aec5cd6fc162cPharma Surgeen2026-07-14T14:57:56.000ZVacaciones de Invierno en el Museo de Química y Farmaciahttps://www.pharmaradar360.com/article/uk-research-and-innovation-publishes-2025-to-2026-annual-report-fc44c978c0417be6Pharma Surgeen2026-07-14T14:57:54.000ZUK Research and Innovation publishes 2025 to 2026 annual reporthttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-la-unlp-70244ab8c5384bacPharma Surgeen2026-07-14T14:55:57.000ZVacaciones de Invierno en la UNLPhttps://www.pharmaradar360.com/article/biotech-companies-tout-benefits-of-ai-assisted-drug-development-3e0d21e6183cafd9Pharma Surgeen2026-07-14T14:55:35.000ZBiotech companies tout benefits of AI-assisted drug developmenthttps://www.pharmaradar360.com/article/seatbelts-still-essential-but-nearly-9-in-10-pregnant-people-didn-t-achieve-reco-e1dc01e66b779ddbPharma Surgeen2026-07-14T14:55:00.000ZSeatbelts still essential, but nearly 9 in 10 pregnant people didn’t achieve recommended seatbelt placement: studyhttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-planetario-unlp-442f8cfb32e11374Pharma Surgeen2026-07-14T14:54:55.000ZVacaciones de Invierno en el Planetario UNLPhttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-la-facultad-de-cs-astronomicas-y-geofisicas-2bdb44ce8a3ae088Pharma Surgeen2026-07-14T14:52:51.000ZVacaciones de Invierno en la Facultad de Cs. Astronómicas y Geofísicashttps://www.pharmaradar360.com/article/his-majesty-the-king-officially-opens-the-uk-space-and-defence-gateway-8cd24c047b8c8f82Pharma Surgeen2026-07-14T14:52:50.000ZHis Majesty the King officially opens the UK Space and Defence Gatewayhttps://www.pharmaradar360.com/article/after-k-rustom-fda-suspends-licences-of-mumbai-s-iconic-shalimar-noor-mohammadi-794fa499a6a38544Pharma Surgeen2026-07-14T14:52:13.000ZAfter K Rustom, FDA suspends licences of Mumbai’s iconic Shalimar, Noor Mohammadi over alleged hygiene lapseshttps://www.pharmaradar360.com/article/ems-e-top-of-mind-pelo-quinto-ano-consecutivo-aponta-datafolha-fb80ecf6ad5f07cePharma Surgeen2026-07-14T14:52:10.000ZEMS é Top of Mind pelo quinto ano consecutivo, aponta Datafolhahttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-mundo-nuevo-dcd0d754f1830b25Pharma Surgeen2026-07-14T14:50:32.000ZVacaciones de Invierno en Mundo Nuevohttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-museo-de-la-plata-0813d15a24828925Pharma Surgeen2026-07-14T14:47:06.000ZVacaciones de Invierno en el Museo de La Platahttps://www.pharmaradar360.com/article/akero-team-backed-by-fairmount-launches-new-immunology-company-ff41db2f427fe540Pharma Surgeen2026-07-14T14:46:49.000ZAkero team, backed by Fairmount, launches new immunology companyhttps://www.pharmaradar360.com/article/h-c-wainwright-reiterates-ionis-stock-rating-on-trial-dosing-9d81d7887a4dcbdcPharma Surgeen2026-07-14T14:44:42.000ZH.C. Wainwright reiterates Ionis stock rating on trial dosinghttps://www.pharmaradar360.com/article/marco-historico-para-o-pais-afirma-alexandre-padilha-sobre-nova-fabrica-da-ems-ef90d5276646d8dePharma Surgeen2026-07-14T14:34:47.000Z“Marco histórico para o país”, afirma Alexandre Padilha sobre nova fábrica da EMShttps://www.pharmaradar360.com/article/cellares-recent-automated-cell-therapy-wins-have-opened-the-biotech-floodgates-dfeb49278fd2cf01Pharma Surgeen2026-07-14T14:26:00.000ZCellares' recent automated cell therapy wins have 'opened the biotech floodgates'https://www.pharmaradar360.com/article/pharma-m-a-roundup-astrazeneca-enters-license-deal-with-dizal-pharmaceutical-cha-97c4be2ea558fc39Pharma Surgeen2026-07-14T14:22:56.000ZPharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeuticshttps://www.pharmaradar360.com/article/russian-billionaire-wins-fight-to-boot-manager-of-biotech-fund-e1d9752acaf9ed91Pharma Surgeen2026-07-14T14:15:09.000ZRussian billionaire wins fight to boot manager of biotech fundhttps://www.pharmaradar360.com/article/nihr-sphr-fellowships-in-public-health-research-2026-390fc89853010f9fPharma Surgeen2026-07-14T14:14:20.000ZNIHR SPHR fellowships in public health research 2026https://www.pharmaradar360.com/article/biotech-visionary-john-f-crowley-to-keynote-emily-whitehead-foundation-s-2026-be-89d22fbe02d868b7Pharma Surgeen2026-07-14T14:10:00.000ZBiotech Visionary John F. Crowley to Keynote Emily Whitehead Foundation's 2026 Believe Ball in Philadelphiahttps://www.pharmaradar360.com/article/transparency-data-medicines-and-healthcare-products-regulatory-agency-privacy-no-850c32c5410b0cb8Pharma Surgeen2026-07-14T14:07:17.000ZTransparency data: Medicines and Healthcare products Regulatory Agency Privacy Noticehttps://www.pharmaradar360.com/article/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state-f0d871bdab45e9c4Pharma Surgeen2026-07-14T14:06:14.000ZMedicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by Statehttps://www.pharmaradar360.com/article/recognized-educator-karenbeth-bohan-retires-from-sopps-f662e98f341203ddPharma Surgeen2026-07-14T14:00:54.000ZRecognized educator KarenBeth Bohan retires from SOPPShttps://www.pharmaradar360.com/article/clinical-success-for-cns-mabs-depends-on-more-than-mechanisms-of-action-alone-1e1b5a00e219f60fPharma Surgeen2026-07-14T14:00:34.000ZClinical success for CNS mAbs depends on more than mechanisms of action alonehttps://www.pharmaradar360.com/article/madden-nfl-27-arcade-edition-brings-gridiron-action-to-apple-arcade-on-august-6-030bac555e2fd462Pharma Surgeen2026-07-14T13:59:25.000ZMadden NFL 27 Arcade Edition brings gridiron action to Apple Arcade on August 6https://www.pharmaradar360.com/article/la-unlp-acordo-mejorar-la-frecuencia-del-talp-y-beneficia-a-miles-de-estudiantes-4f1d8fde652f5233Pharma Surgeen2026-07-14T13:57:59.000ZLa UNLP acordó mejorar la frecuencia del TALP y beneficia a miles de estudiantes del conurbanohttps://www.pharmaradar360.com/article/glasgow-fair-public-holiday-reminder-0f4ff97fdfdca836Pharma Surgeen2026-07-14T13:52:50.000ZGlasgow Fair public holiday reminderhttps://www.pharmaradar360.com/article/biotech-funding-gap-widens-despite-rebound-in-vc-investment-b1559510585c639dPharma Surgeen2026-07-14T13:43:47.000ZBiotech funding gap widens despite rebound in VC investmenthttps://www.pharmaradar360.com/article/biogen-plans-phase-3-trial-for-alzheimer-s-drug-diranersen-by-investing-com-4f99c61db4d6a5d9Pharma Surgeen2026-07-14T13:38:36.000ZBiogen plans phase 3 trial for Alzheimer’s drug diranersen By Investing.comhttps://www.pharmaradar360.com/article/ipos-juice-biotech-real-estate-if-only-a-little-but-vacancy-still-climbs-and-lea-0a22cf5df7824679Pharma Surgeen2026-07-14T13:38:00.000ZIPOs juice biotech real estate (if only a little), but vacancy still climbs and lease rates tumblehttps://www.pharmaradar360.com/article/biogen-plans-phase-3-trial-for-alzheimer-s-drug-diranersen-by-investing-com-e0436137a651bfedPharma Surgeen2026-07-14T13:32:55.000ZBiogen plans phase 3 trial for Alzheimer’s drug diranersen By Investing.comhttps://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-report-q2-2026-7c808e6c9251c844Pharma Surgeen2026-07-14T13:32:30.000ZTuberculosis in England national quarterly report: Q2 2026https://www.pharmaradar360.com/article/pharmaceutical-manufacturing-validation-batch-integrity-and-what-a-cyber-inciden-d902f3316c9ecc8ePharma Surgeen2026-07-14T13:31:26.000ZPharmaceutical manufacturing: Validation, batch integrity, and what a cyber incident actually costshttps://www.pharmaradar360.com/article/peticion-para-reconocer-el-ecocidio-crimen-de-lesa-humanidad-bf9f00b9b3c5bff8Pharma Surgeen2026-07-14T13:29:20.000ZPetición para reconocer el Ecocidio Crimen de Lesa Humanidadhttps://www.pharmaradar360.com/article/eating-chili-peppers-may-raise-the-risk-of-one-deadly-cancer-183ee83a03a94a61Pharma Surgeen2026-07-14T13:27:21.000ZEating chili peppers may raise the risk of one deadly cancerhttps://www.pharmaradar360.com/article/shortly-after-bankruptcy-io-biotech-founder-takes-on-new-top-position-761179ae01b38ee3Pharma Surgeen2026-07-14T13:26:24.000ZShortly after bankruptcy: IO Biotech founder takes on new top positionhttps://www.pharmaradar360.com/article/germany-passes-bill-despite-criticism-from-pharmaceutical-companies-381e48fe3471214bPharma Surgeen2026-07-14T13:21:00.000ZGermany passes bill despite criticism from pharmaceutical companieshttps://www.pharmaradar360.com/article/novel-vaccine-framework-illustrates-promise-for-oral-cancer-vaccines-951bffa5c2516866Pharma Surgeen2026-07-14T13:19:28.000ZNovel vaccine framework illustrates promise for oral cancer vaccineshttps://www.pharmaradar360.com/article/summit-sells-failed-antibiotic-to-openai-backed-startup-in-105m-deal-9273ccc176c89b05Pharma Surgeen2026-07-14T13:17:45.000ZSummit sells failed antibiotic to OpenAI-backed startup in $105M dealhttps://www.pharmaradar360.com/article/biogen-data-highlight-promise-questions-surrounding-tau-targeting-alzheimer-s-dr-32078bd05605f6b5Pharma Surgeen2026-07-14T13:17:45.000ZBiogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugshttps://www.pharmaradar360.com/article/cordis-project-antibiotic-resistance-socio-economic-determinants-and-the-role-of-d7523d8a992a7c8aPharma Surgeen2026-07-14T13:17:31.000ZCORDIS project: Antibiotic Resistance: Socio-Economic Determinants and the Role of Information and Salience in Treatment Choicehttps://www.pharmaradar360.com/article/cordis-project-comprehensive-platform-for-the-functional-characterization-of-can-4a73c324c493fbbaPharma Surgeen2026-07-14T13:17:16.000ZCORDIS project: Comprehensive Platform for the Functional Characterization of Cancer Epigenetics and Diagnosishttps://www.pharmaradar360.com/article/cordis-project-ebrains-2-0-a-research-infrastructure-to-advance-neuroscience-and-554e083b8a023288Pharma Surgeen2026-07-14T13:16:31.000ZCORDIS project: EBRAINS 2.0: A Research Infrastructure to Advance Neuroscience and Brain Healthhttps://www.pharmaradar360.com/article/cordis-project-development-and-evaluation-of-radical-oxygen-species-ros-responsi-ba01ff65cbf2235aPharma Surgeen2026-07-14T13:16:04.000ZCORDIS project: Development and evaluation of Radical Oxygen Species (ROS)-responsive drug delivery systems to prevent and cure inflammatory and hypoxic diseases.https://www.pharmaradar360.com/article/trusted-cheminformatics-zero-integration-headaches-ml-in-python-with-chemaxon-fbeb10a2862dd3e4Pharma Surgeen2026-07-14T13:04:38.000ZTrusted Cheminformatics, Zero Integration Headaches: ML in Python with Chemaxonhttps://www.pharmaradar360.com/article/988-enters-its-fourth-year-as-demand-grows-and-the-mental-health-and-substance-u-7e8bb9493d628ddePharma Surgeen2026-07-14T13:00:00.000Z988 Enters Its Fourth Year as Demand Grows and the Mental Health and Substance Use Landscape Shiftshttps://www.pharmaradar360.com/article/3-things-to-know-about-substance-use-and-suicide-mortality-e8f57c131d2011dbPharma Surgeen2026-07-14T13:00:00.000Z3 Things to Know About Substance Use and Suicide Mortalityhttps://www.pharmaradar360.com/article/danish-biotech-sells-future-royalties-to-bring-its-first-product-to-market-d417c94ec89d2298Pharma Surgeen2026-07-14T12:59:00.000ZDanish biotech sells future royalties to bring its first product to markethttps://www.pharmaradar360.com/article/adneuris-therapeutics-grants-exclusive-license-to-zhejiang-conba-pharmaceutical-df5184412e1ae8f8Pharma Surgeen2026-07-14T12:52:53.000ZAdneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater Chinahttps://www.pharmaradar360.com/article/the-new-era-of-pharma-distribution-balancing-precision-and-scale-11eec0ed16e6e3fcPharma Surgeen2026-07-14T12:39:35.000ZThe New Era of Pharma Distribution: Balancing Precision and Scalehttps://www.pharmaradar360.com/article/surgical-infections-cost-hospitals-billions-one-under-the-radar-biotech-player-m-fc320956fc36df3cPharma Surgeen2026-07-14T12:30:05.000ZSurgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change Thathttps://www.pharmaradar360.com/article/steering-the-formation-of-engineered-tissue-by-sound-waves-6c6f0718283a8903Pharma Surgeen2026-07-14T12:28:52.000ZSteering the Formation of Engineered Tissue by Sound Waveshttps://www.pharmaradar360.com/article/menb-vaccination-programme-eligible-residential-further-education-settings-ea1c926b97083608Pharma Surgeen2026-07-14T12:22:55.000ZMenB vaccination programme: eligible residential further education settingshttps://www.pharmaradar360.com/article/la-aemps-informa-de-que-la-ue-amplia-a-81-el-numero-de-alergenos-de-fragancias-q-324a51990a9aced2Pharma Surgeen2026-07-14T12:19:42.000ZLa AEMPS informa de que la UE amplía a 81 el número de alérgenos de fragancias que deberán etiquetarse en el listado de ingredientes de cosméticoshttps://www.pharmaradar360.com/article/kemri-delivers-on-ebola-preparedness-pledge-with-critical-ipc-supplies-589164f5884aaa2fPharma Surgeen2026-07-14T12:17:51.000ZKEMRI Delivers on Ebola Preparedness Pledge with Critical IPC Supplieshttps://www.pharmaradar360.com/article/can-fite-secures-australian-patent-allowance-supporting-namodenoson-development-9cbb740e30a2b80ePharma Surgeen2026-07-14T12:14:29.000ZCan-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancerhttps://www.pharmaradar360.com/article/ai-ml-in-practice-machine-learning-prediction-of-chromatographic-retention-times-85adbf7f79585669Pharma Surgeen2026-07-14T12:11:14.000ZAI/ML in Practice: Machine-learning Prediction of Chromatographic Retention Times for Small Molecules in Pharmaceutical Applicationshttps://www.pharmaradar360.com/article/compass-has-two-positive-phase-3-trials-the-fda-has-final-guidance-so-why-does-p-51e04535f6c64361Pharma Surgeen2026-07-14T12:09:16.000ZCompass Has Two Positive Phase 3 Trials. The FDA Has Final Guidance. So Why Does Psilocybin Still Feel Like a Gamble?https://www.pharmaradar360.com/article/campus-less-accessible-due-to-resurfacing-of-abram-van-rijckevorselweg-3cf121b31486ff02Pharma Surgeen2026-07-14T12:07:55.000ZCampus less accessible due to resurfacing of Abram van Rijckevorselweghttps://www.pharmaradar360.com/article/progress-in-food-fortification-highlighted-as-experts-call-for-stronger-action-a-a00c3e3659957dbcPharma Surgeen2026-07-14T12:07:42.000ZProgress in Food Fortification Highlighted as Experts Call for Stronger Action Across Eastern and Southern Africahttps://www.pharmaradar360.com/article/skinmedica-deepens-commitment-to-regenerative-science-with-continued-investment-a98b88dc5dbb7778Pharma Surgeen2026-07-14T12:05:00.000ZSkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Developmenthttps://www.pharmaradar360.com/article/gemelos-digitales-la-revolucion-tecnologica-que-obliga-a-debatir-privacidad-dere-a849959c910684e5Pharma Surgeen2026-07-14T12:02:18.000ZGemelos digitales: la revolución tecnológica que obliga a debatir privacidad, derechos y algoritmoshttps://www.pharmaradar360.com/article/fda-issues-proposal-to-streamline-registration-for-advanced-distributed-manufact-22f4e479c4bf9295Pharma Surgeen2026-07-14T12:00:27.000ZFDA Issues Proposal to Streamline Registration for Advanced Distributed Manufacturershttps://www.pharmaradar360.com/article/dolphins-dropping-in-to-the-sea-of-japan-e47fdbf7f129b122Pharma Surgeen2026-07-14T12:00:00.000ZDolphins dropping in to the Sea of Japanhttps://www.pharmaradar360.com/article/mainshock-locations-shape-earthquake-size-distributions-59f30b10df8e1f21Pharma Surgeen2026-07-14T12:00:00.000ZMainshock locations shape earthquake size distributionshttps://www.pharmaradar360.com/article/small-differences-in-classroom-ranking-can-shape-secondary-school-advice-fe130732d891418bPharma Surgeen2026-07-14T12:00:00.000ZSmall differences in classroom ranking can shape secondary school advicehttps://www.pharmaradar360.com/article/element-biosciences-prevails-in-german-patent-case-against-illumina-b3b817f2da7d1d45Pharma Surgeen2026-07-14T12:00:00.000ZElement Biosciences Prevails in German Patent Case Against Illuminahttps://www.pharmaradar360.com/article/end-to-end-traceability-connecting-source-systems-and-tmf-7b13c90b49b3989ePharma Surgeen2026-07-14T12:00:00.000ZEnd-to-End Traceability: Connecting Source, Systems, and TMFhttps://www.pharmaradar360.com/article/inhibikase-therapeutics-announces-sale-of-50-million-of-shares-through-its-at-th-fce7b17f6db491c9Pharma Surgeen2026-07-14T12:00:00.000ZInhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facilityhttps://www.pharmaradar360.com/article/investigadores-de-la-unlp-y-del-conicet-se-preparan-para-la-nueva-era-de-alta-lu-526228d8bfd86729Pharma Surgeen2026-07-14T11:58:25.000ZInvestigadores de la UNLP y del CONICET se preparan para la nueva era de “alta luminosidad” de la física de partículashttps://www.pharmaradar360.com/article/emergenza-ondate-di-calore-attivo-cold-spot-al-policlinico-di-milano-contro-i-di-3f7f644104fc411cPharma Surgeen2026-07-14T11:56:00.000ZEmergenza ondate di calore: attivo Cold Spot al Policlinico di Milano contro i disturbi da caldo intensohttps://www.pharmaradar360.com/article/germany-pharmaceutical-grade-polyethylene-glycol-market-analysis-forecast-size-t-ac8c97c2759e06cdPharma Surgeen2026-07-14T11:52:07.000ZGermany Pharmaceutical Grade Polyethylene Glycol - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/recent-cancer-trial-failures-and-setbacks-a-quick-look-42d51efe755f5578Pharma Surgeen2026-07-14T11:46:41.000ZRecent Cancer Trial Failures and Setbacks: A Quick Lookhttps://www.pharmaradar360.com/article/vota-l-archivio-storico-del-policlinico-di-milano-fra-i-luoghi-del-cuore-fai-805384554a64d0efPharma Surgeen2026-07-14T11:38:00.000ZVota l’Archivio Storico del Policlinico di Milano fra "I Luoghi del cuore FAI"https://www.pharmaradar360.com/article/pharma-facilities-begin-gateway-rollout-with-up-to-4x-faster-screening-c1caff65e77b66a1Pharma Surgeen2026-07-14T11:30:00.000ZPharma Facilities Begin Gateway Rollout With Up to 4x Faster Screeninghttps://www.pharmaradar360.com/article/preterm-birth-impacts-early-educational-achievements-face31a4a8abacb3Pharma Surgeen2026-07-14T11:20:17.000ZPreterm birth impacts early educational achievementshttps://www.pharmaradar360.com/article/die-kunst-des-im-wandel-seins-2077620d94aac233Pharma Surgeen2026-07-14T11:17:01.000ZDie Kunst des „Im Wandel-Seins“https://www.pharmaradar360.com/article/agenus-stock-doubles-as-biotech-narrows-phase-3-bet-ff97219e0d6ea283Pharma Surgeen2026-07-14T11:17:00.000ZAgenus stock doubles as biotech narrows Phase 3 bethttps://www.pharmaradar360.com/article/ai-biopharma-biossil-plans-to-advance-experimental-c-diff-drug-a822bb3813fed51aPharma Surgeen2026-07-14T11:07:14.000ZAI Biopharma Biossil Plans to Advance Experimental C. diff Drughttps://www.pharmaradar360.com/article/hepatitis-e-has-no-approved-treatments-as-atea-begins-human-trial-7ebed53cc2c67ad0Pharma Surgeen2026-07-14T11:00:00.000ZHepatitis E Has No Approved Treatments as Atea Begins Human Trialhttps://www.pharmaradar360.com/article/can-fite-s-namodenoson-in-phase-3-liver-cancer-study-pancreatic-trial-planned-3bcdb8879c5bea92Pharma Surgeen2026-07-14T11:00:00.000ZCan-Fite's Namodenoson in Phase 3 liver cancer study; pancreatic trial plannedhttps://www.pharmaradar360.com/article/summit-therapeutics-signs-agreement-to-sell-phase-iii-asset-ridinilazole-to-bios-babe1e65b5e9fe5dPharma Surgeen2026-07-14T11:00:00.000ZSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.https://www.pharmaradar360.com/article/new-map-shows-how-pharmaceuticals-support-jobs-health-and-growth-across-every-uk-d752ae113c772fa1Pharma Surgeen2026-07-14T10:59:54.000ZNew map shows how pharmaceuticals support jobs, health and growth across every UK nationhttps://www.pharmaradar360.com/article/catching-the-drift-how-wildfire-smoke-plumes-may-increase-cancer-risk-db8e7b2f5dceea70Pharma Surgeen2026-07-14T10:57:34.000ZCatching the Drift: How Wildfire Smoke Plumes May Increase Cancer Riskhttps://www.pharmaradar360.com/article/new-map-shows-how-pharmaceuticals-support-jobs-health-and-growth-across-every-uk-bd057dc21a414301Pharma Surgeen2026-07-14T10:55:59.000ZNew map shows how pharmaceuticals support jobs, health and growth across every UK nationhttps://www.pharmaradar360.com/article/european-biotech-chases-record-vc-funding-a3776ba34e3dfb6cPharma Surgeen2026-07-14T10:53:36.000ZEuropean biotech chases record VC fundinghttps://www.pharmaradar360.com/article/fortrea-mdd-advancing-diagnostic-imaging-trials-through-global-experience-e9d52a44cf6e4246Pharma Surgeen2026-07-14T10:50:06.000ZFortrea MDD: Advancing diagnostic imaging trials through global experiencehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-mycenax-biotech-inc-tpex-4726-47862dba646287b8Pharma Surgeen2026-07-14T10:43:14.000ZEnterprise value to EBITDA forward of Mycenax Biotech Inc. – TPEX:4726https://www.pharmaradar360.com/article/unpaid-carers-action-plan-recognise-refer-reach-9e6352a24c35b04aPharma Surgeen2026-07-14T10:42:29.000ZUnpaid carers action plan: recognise, refer, reachhttps://www.pharmaradar360.com/article/biotech-infrastructure-review-where-investment-is-flowing-84227229c8d8aad6Pharma Surgeen2026-07-14T10:32:14.000ZBiotech infrastructure review: where investment is flowinghttps://www.pharmaradar360.com/article/cathay-biotech-and-unit-file-trade-secret-infringement-lawsuit-8e062eb4314528afPharma Surgeen2026-07-14T10:32:04.000ZCathay Biotech And Unit File Trade Secret Infringement Lawsuithttps://www.pharmaradar360.com/article/atrium-s-first-prkag2-trial-to-evaluate-treatment-for-disease-cause-da250a8a72b76ed6Pharma Surgeen2026-07-14T10:30:00.000ZAtrium's First PRKAG2 Trial to Evaluate Treatment for Disease Causehttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-license-collaboration-and-strategic-inves-77d6f1deca86eb20Pharma Surgeen2026-07-14T10:20:05.000ZHansoh Pharmaceutical : PHARMA ANNOUNCES LICENSE COLLABORATION AND STRATEGIC INVESTMENT WITH AVERE FOR ORAL IL‑23 ASSET HS‑20118https://www.pharmaradar360.com/article/shampoo-chemicals-in-your-milk-2-crore-adulteration-racket-exposed-in-maharashtr-8c2b6e5c75ba4a29Pharma Surgeen2026-07-14T10:13:01.000ZShampoo, chemicals in your milk? ₹2 crore adulteration racket exposed in Maharashtra